A polyglutamine expansion within the ataxin-1 protein (ATXN1) underlies spinocerebellar ataxia type-1 (SCA1), a neurological disorder mainly characterized by ataxia and cerebellar deficits. In SCA1, both loss and gain of ATXN1 biological functions contribute to cerebellar pathogenesis. However, the critical ATXN1 functions and pathways involved remain unclear. To further investigate the early signalling pathways regulated by ATXN1, we performed an unbiased proteomic study of the Atxn1-KO 5-week-old mice cerebellum. Here, we show that lack of ATXN1 expression induces early alterations in proteins involved in glycolysis [pyruvate kinase, muscle, isoform 1 protein (PKM-i1), citrate synthase (CS), glycerol-3-phosphate dehydrogenase 2 (GPD2), glucose-6-phosphate isomerase (GPI), alpha-enolase (ENO1)], ATP synthesis [CS, Succinate dehydrogenase complex,subunit A (SDHA), ATP synthase subunit d, mitochondrial (ATP5H)] and oxidative stress [peroxiredoxin-6 (PRDX6), aldehyde dehydrogenase family 1, subfamily A1, 10-formyltetrahydrofolate dehydrogenase]. In the SCA1 mice, several of these proteins (PKM-i1, ATP5H, PRDX6, proteome subunit A6) were down-regulated and ATP levels decreased. The underlying mechanism does not involve modulation of mitochondrial biogenesis, but dysregulation of the activity of the metabolic regulators glycogen synthase kinase 3B (GSK3b), decreased in Atxn1-KO and increased in SCA1 mice, and mechanistic target of rapamycin (serine/threonine kinase) (mTOR), unchanged in the Atxn1-KO and decreased in SCA1 mice cerebellum before the onset of ataxic symptoms. Pharmacological inhibition of GSK3b and activation of mTOR in a SCA1 cell model ameliorated identified ATXN1-regulated metabolic proteome and ATP alterations. Taken together, these results point to an early role of ATXN1 in the regulation of bioenergetics homeostasis in the mouse cerebellum. Moreover, data suggest GSK3b and mTOR pathways modulate this ATXN1 function in SCA1 pathogenesis that could be targeted therapeutically prior to the onset of disease symptoms in SCA1 and other pathologies involving dysregulation of ATXN1 functions.
Introduction
A polyglutamine expansion mutation conferring both gain and loss of functions to the ataxin-1 protein (ATXN1) triggers variable cerebellar atrophy, progressive dysfunction of Purkinje cells (PCs), ataxia and cerebellar motor deficits in spinocerebellar ataxia type 1 (SCA1, OMIM #164400) (1, 2) . The molecular pathology in SCA1 is determined by the expansion of CAG repeats within the ATXN1 gene thus encoding varying size string of glutamine amino acids in the ATXN1 protein. When this expansion of glutamines exceeds a threshold set at $40 repeats, the functions of ATXN1 are altered and SCA1 pathogenesis ensues. Similarly to other neurological diseases caused by polyglutamine expansions, including Huntington's disease (OMIM #143100), Kennedy's (OMIM #313200) and six additional SCAs, the mutation within otherwise different proteins, triggers mitochondrial damage, neurofilament accumulations, dendritic atrophy and protein aggregation among others in the affected neurons (3) (4) (5) (6) . Although these disorders have similar features and their genotype-phenotype correlations are highly significant determinants, the pathophysiological mechanisms are unclear and there is currently no therapy to suppress or delay the onset of the neurological symptoms.
ATXN1 is a 98 kDa evolutionarily conserved protein involved in transcriptional regulation and cell signalling pathways implicating Capicua, Notch, specificity protein 1 transcription factor (Sp1), glutamate, dopamine receptor D2 (DRD2), wingless-type MMTV integration site family, member 1 (WNT), protein phosphatase 2, now known as PP2 (PP2A) and also RNA processing through interaction with RNA binding motif protein 17 (RBM17) (6) (7) (8) (9) (10) (11) (12) (13) (14) . ATXN1 is best known for its role in SCA1, but the ATXN1 gene has also been implicated in other neurological conditions such as Alzheimer's disease (AD), autism and amyotrophic lateral sclerosis (ALS) (15) (16) (17) (18) (19) . ATXN1 functions are defined by its interactions and assembly unto distinct protein complexes being able to both repress and activate gene expression or modulate enzymatic activities (11, 13, (20) (21) (22) (23) (24) . Many of the functions of ATXN1 have been characterized in the Atxn1 knock-out mice (Atxn1-KO) which do not exhibit ataxia but present with neurocognitive deficits, specifically motor learning and alterations in signalling pathways underlying cerebellar motor functions (6, 10, 13, 25, 26) . This evidence along with the peak of expression in the postnatal mouse cerebellum supports a predominant function of ATXN1 in cerebellar development and homeostasis (27, 28) . ATXN1 mediated alterations during early development play a critical role in the course and severity of SCA1 symptoms. This was clearly demonstrated using a conditional transgenic SCA1 model showing that expression of the mutant ATXN1 during early development but not later results in full presentation of symptoms (27) . This effect appears mediated by RAR-related orphan receptor A (RORA) since unlike the wild-type (WT) protein, the mutant ATXN1 was unable to activate the RORA-60 kDa Tat-interactive protein (TIP60) complex resulting in the down-regulation of RORA-regulated genes in the SCA1 mouse model (11, 27, 29) . The developmental regulator Notch intracellular domain (NICD) is also regulated by ATXN1 as it competes for binding with the C-promoter-binding factor 1 (CPBF1) which normally functions as a transcriptional activator of the Notchregulated genes when bound to NICD (30) .
ATXN1 has also been shown to modulate PP2A phosphatase known to play important signalling roles during development and homeostasis. This phosphatase is of particular interest since a mutation within the region regulating the expression of PP2A regulatory subunit B beta (PPP2R2B) gene, encoding a regulator subunit of PP2A, is known to underlie SCA12 (OMIM #6043269) (31) (32) (33) . This form of spinocerebellar ataxia is also characterized by cerebellar neurodegeneration (13, 20) . Moreover, ATXN1 does not only physically interact with ANP32A, a PP2A endogenous inhibitor, but also differentially regulates its expression and that of the PP2A regulatory subunit B beta protein (PP2A Bb) (13, 20) . In addition, ATXN1 regulates the phosphorylation-induced activation of the PP2A regulatory subunit B56 delta (13) . Interestingly, PP2A was shown to regulate the ATXN1 ser776 phosphosite found important in SCA1 pathogenesis (34) . The expression of the mutant ATXN1 [82Q] or that of the phosphosite mutant ATXN1[30Q]-D776 induce SCA1 symptoms in mice, alter cerebellar PC and climbing fibre innervation and PC dendritic pruning during development (28, 35) . Importantly, the effects of the mutant ATXN1 protein on the disease phenotypes in the conditional mouse SCA1 model were shown to be reversible (36) . However, whether ATXN1 phosphorylation enhances or suppresses normal functions or whether it confers new functions to ATXN1 protein remains unclear. Post-translational modifications such as phosphorylation are known to induce protein conformational changes that may confer ATXN1 altered or gain of functions leading to pathogenesis. In fact, oligomerization and/or conformational changes in ATXN1 are linked to pathogenesis in SCA1 and other polyglutamine disorders (5, 37) . Furthermore, oligomer formation and very importantly those protein interactors like capicua which stabilize oligomers appear to contribute to mutant ATXN1 toxicity in SCA1 (38) . Taken together these works suggest a regulatory feedback-loop between ATXN1 and PP2A.
Alterations in PP2A can also induce mitochondria dysfunction, a common feature of many neurodegenerative disorders including the SCAs (13, (31) (32) (33) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) . Mitochondria are critical for energy generation derived from catabolism of carbohydrates and fatty acids through oxidative phosphorylation. Recent work reported an increase in the catabolic metabolism in SCA1 patients, which appears to contribute to their weight loss (45) . Neurochemical profile alterations indicative of metabolic changes and oxidative stress were also identified in presymptomatic SCA1 knock-in mouse model (SCA1-KI) and in SCA1 patients (41, 45, 49) . However, the mechanism by which these metabolic alterations are induced in SCA1 is not understood. That disruption in mitochondria functions could cause ataxia is well supported by identified mutations in genes from either the mitochondrial or nuclear genome resulting in different neurological conditions presenting with ataxia. These include mutations in mitochondrially encoded ATP6 gene (ATP6) causing neuropathy, ataxia or retinitis pigmentosa (NARP, OMIM #551500) (50) (51) (52) . AFG3-like AAA ATPase 2 (AFG3L2) mutations in spinocerebellar ataxia subtype 28, SCA28 (OMIM #610246) and autosomal recessive spastic ataxia of CharlevoixSaguenay (ARSACS, OMIM #270550) caused by mutations in the sacsin (SACS) gene involved in the mitochondrial fission-fusion dynamics (53) . Furthermore, mitochondrial DNA (mtDNA) damage has recently been reported in the cerebellum of the SCA1-KI mouse model that can be ameliorated together with ataxic symptoms by exogenous expression of the DNA repair protein high mobility group (HMG) binding protein 1 (HMGB1) (47, 54, 55) . Mutations in genes involved in mtDNA repair, replication or transcription such as C10ORF2, DNA polymerase subunit gamma (POLG) or spastic paraplegia 7 (SPG7) result in some features resembling SCAs, while Aprataxin and tyrosyl-DNA phosphodiesterase 1 (TDP1) are known to underlie cerebellar neurodegeneration in Ataxia oculomotor apraxia type 1 (AOA1) and spinocerebellar ataxia type 17 (SCA17) (56) (57) (58) . Altogether, these lines of evidence show that the cerebellum is highly sensitive to mitochondria functions.
To gain further insights into the normal cellular functions of ATXN1 and particularly those that contribute to the early events leading to cerebellar pathogenesis in SCA1, we performed an unbiased proteomic study of the mouse cerebellar proteome and identified predominant changes in proteins involved in energy metabolism. Specifically, we show that lack of ATXN1 expression induces an early up-regulation of proteome involved in the tricarboxylic acid cycle (TCA cycle), ATP and oxidative stress suggesting a role for ATXN1 in the modulation of the bioenergetics machinery in the mouse cerebellum. On the other hand, expression of mutant ATXN1 in the transgenic SCA1 mouse model-induced decreased levels of pyruvate kinase, muscle, isoform 1 protein (PKM-i1), peroxiredoxin-6 (PRDX6) and ATP synthase subunit d, mitochondrial (ATP5H) and resulted in lower ATP levels in a cell and mouse model of SCA1. Moreover, nutrient metabolism regulating pathways glycogen synthase kinase 3B (GSK3b) and mechanistic target of rapamycin (serine/threonine kinase) (mTOR) were found differentially altered in mice lacking expression of ATXN1 and in the mice expressing the mutant ATXN1. Remarkably, pharmacological modulation of these pathways appears to prevent some of the ATXN1-regulated proteome changes detected in a SCA1 cell model. These data highlight a role for ATXN1 in the regulation of bioenergetics and the presence of early metabolic alterations in the cerebellum of the SCA1 mice that could be targeted therapeutically prior to the onset of ataxia.
Results

ATXN1-regulated cerebellar proteome is enriched for metabolic proteins
At 5 weeks of age, before the onset of ataxic symptoms, the SCA1 transgenic mice present significant transcriptional alterations contributed by loss of ATXN1 due to its relevant role as a transcriptional co-regulator (2, 13, 23, 59) . However, it is not clear which transcriptional or post-transcriptional ATXN1-regulated changes are reflected at the proteome and at the functional level. To address this question, we analysed the ATXN1-regulated proteome by two-dimensional difference in gel electrophoresis (2D-DIGE). A representative image of a 12.5% polyacrylamide gel is shown in Figure 1A . The non-linear progenesis samespot software v3.0 (Non-Linear Dynamics) enabled the identification of a total of 989 protein spots in the 2D gels. Image quantification and statistical analysis revealed 19 protein spots that exhibited statistically significant level changes in the Atxn1-KO compared with WT mice which were then subjected to mass spectroscopy (Fig. 1A) . Of these, a total of 13 proteins were successfully identified by mass spectrometry (MS) (Fig. 1B) . Of the 13 proteins identified, 4 of them [PKM-i1, glucose-6-phosphate isomerase (GPI), alpha-enolase (ENO1), glycerol-3-phosphate dehydrogenase 2 (GPD2)] are involved in glycolysis, 2 proteins (Succinate dehydrogenase complex, subunit A (SDHA) and ATP5H) are components of subunits II and V of the oxidative phosphorylation chain, respectively, citrate synthase (CS) is a critical component of the TCA cycle and fatty acid synthesis when transported to the cytoplasm, and PRDX6 and the two aldehyde dehydrogenase proteins, 10-formyltetrahydrofolate dehydrogenase (ALDH1L1) and aldehyde dehydrogenase family 1, subfamily A1 (ALDH1A1) are involved in balancing oxidative stress. Proteome subunit A6 (PSA6) is a protein component of the proteasome involved in cellular proteolysis. The remaining two proteins are implicated in cellular homeostasis with WD repeat domain 1 (WDR1) regulating the actin cytoskeleton and DEAD (Asp-Glu-Ala-Asp) box helicase 1 (DDX1) functioning in RNA metabolism.
All the proteome changes tested from the cerebellum of the 5-week-old Atxn1-KO mouse were validated by quantitative immunoblotting. Increased abundance from 1.2-to 1.8-fold was detected for ATP5H [F (1, 10) Fig. S1 ).
To begin to examine the relationship between the ATXN1-regulated proteins, we performed a functional annotation of the identified proteins using the functional classification tool DAVID Bioinformatics resources 6.7 (Supplementary Material, Table S1 ). This functional tool classifies genes by similarity to the whole genome based on shared functional annotation such as Gene Ontology (GO) terms, using over 75 000 terms from 14 functional annotation sources. A clustering algorithm then groups functionally related genes. To determine which functions are significantly enriched, the program compared the abundance of GO terms for our annotated dataset with the natural abundance of GO terms for the genes in the reference database (Mus musculus) within the same functional categories. The P-value based on the overrepresentation of a specific GO term in our dataset shows the lowest values or most significant enrichment in the catabolic process (GO:0009109, 3 components, P ¼ 1.57E-04), SP_PIR_KEYWORDS mitochondria inner membrane (3 components, P ¼ 0.00445) and glucose metabolic processes (GO:0006006, 3 components, P ¼ 0.00362) (Supplementary Material, Table S1 ). Furthermore, Functional Annotation Clustering of the dataset recognized at least three annotation clusters with significant enrichment scores of 3.04, 1.54 and 1.18 all involving energy metabolic processes (Supplementary Material, Table S1 ). Most of the proteins have catalytic activity suggesting an induction of the energy metabolic pathways in response to the lack of ATXN1 (Fig. 1C) .
The biological relationship between the identified proteome was further analysed using the protein analysis through evolutionary relationships (PANTHER) Classification System Atxn1-KO mice. Levels of aldehyde dehydrogenase 1 family member A1 (Aldh1a1), ATP synthase, Hþ transporting, mitochondrial F0 complex, subunit D (Atp5h), Cs, glycerol phosphate dehydrogenase 2, mitochondrial (Gpd2), glucose phosphate isomerase 1 (Gpi1), pyruvate kinase, muscle Pkm-i1 and peroxiredoxin 6 (Prdx6) levels were quantified by qRT-PCR and expressed relative to B-microglobulin (B2m) levels by the CT-method. Atp5a1 mRNA level was included as a positive control (10) . Representative image of the mRNA quantified by qRT-PCR is shown in C. All values shown are normalized to the average value for the WT mice, which was set to 1 (dotted line). One-way ANOVA and post hoc Tukey HSD was used for statistical analysis, *P < 0.05, **P < 0.005, #P ¼ 0.05 compared with WT controls. Error bars denote SEM. N ¼ 5 each.
(Supplementary Material, Tables S2-S5) (60) . This program classifies proteins based on the evolutionarily related protein families and subfamilies that also have the same function. We first carried out a functional annotation using the PANTHER GO-slim, which uses the PANTHER/X molecular function ontology composed of a selected set of terms from the GO using the commonly used protein function classes. This analysis broadly distributed the components of the ATXN1-regulated proteome into functional categories involved in metabolic processes (GO:008152, 9 components, 75% of all components) and catalytic activity (GO:0003824, 9 components, 75% of all components). (Fig. 1C and Tables S4 and S5 ). The FDR describing the possibility that the detected Go term enrichment may be expected randomly for proteins with similar size in the whole genome was significantly low. This suggests that the functional relationships in the identified proteome are significant even considering the relatively small size dataset. Furthermore, we used the STRING program to study the interactions of the identified proteins among themselves and with other proteins involved in chemical reactions or biological regulatory events in the context of the whole genome (Supplementary Material, Table S6 ). This program examines the dataset using evidence-based curated databases including the interaction of the genes encoding the ATXN1-regulated proteome including their co-expression, location in the same open-reading frame, participation in the same signalling pathway or experimental evidence of physical interaction. The text-mining database was not used for the statistical analysis, and only primary interactions were examined. The protein-protein interaction (PPI) enrichment analysis shows significantly more interactions than expected with a P-value of 3.45E-05. Co-expression and neighbourhood analysis links Sdha with Aldh1a1, Gpd2, Aldh1l1, Atp5h, Eno1 and Cs. The second largest node is around Eno1 with interactions to Gpi, Pkm, Cs, Sdha and Psma. Although all of the proteins encoded by these genes are functionally related through metabolic roles, experimental evidence of the mechanism interconnecting some of these is lacking. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways analysis showed the most enrichment in highly conserved energy metabolism components (KEGG 1120, 5 components, FDR q ¼ 7.56E-06) and one carbon metabolism to generate precursor metabolites (KEGG 1200, 4 components, FDR q ¼ 4.61E-05).
Analysis of the same genes encoding the ATXN1-regulated proteins using the human whole genome database yielded similar results with the oxidation-reduction process being more enriched in human compared with mice (GO:0055114, 10 versus 6 components) and with lower FDR (q ¼ 1.09E-07 versus 0.00114). Similar to mice two of the most overrepresented pathways in human are carbon metabolism and metabolic pathways (KEGG pathway: 1200, 1100; 4 versus 7 components; FDR q ¼ 4.61E-5 versus 0.000339). Taken together the proteome data analysis using the DAVID, PANTHER and STRING annotation tools support the statistically significant enrichment of the proteins regulated by ATXN1 in the metabolic processes of the mouse cerebellum (Fig. 1B and C) . To test whether the ATXN1 roles in transcriptional regulation underlie the identified proteome changes in the mouse cerebellum, quantitative real time polymerase chain reaction (qRT-PCR) was performed on cDNA derived from 5-week-old WT and KO mice mRNA of some of the genes encoding proteins in distinct metabolic process functional clusters; glycolysis (Pkm-i1, Gpd2, Gpi), TCA cycle and oxidative phosphorylation (Cs, Atp5h) and oxidative stress (Prdx6 and Aldh1a1) (Fig. 2C and D) . The primers utilized are listed in Supplementary Material, Table S7 . In addition to the mRNA encoding the identified proteins, we measured the mRNA levels of Atp5a1, another ATPase oxidative phosphorylation subunit previously found increased in microarray studies, as a qRT-PCR positive control (10) . As expected, Atp5a1, showed over a 2-fold increase in the Atxn1-KO mice cerebellum [F (1, 8) (1, 8) ¼ 0.607, P ¼ 0.458] genes do not appear to be transcriptionally regulated by ATXN1, although the first two exhibited changes near statistically significant levels. Interestingly, Atp5h and Gpd2 mRNA levels in the Atxn1-KO mice cerebellum show an inversely proportional trend to the protein level, which while not reaching statistical significance, is suggestive of positive and negative post-transcriptional regulation by ATXN1, respectively ( Altered cerebellar glycolysis but not ATP synthesis in the absence of ATXN1
To investigate whether the proteome alterations identified in the cerebellum of Atxn1-KO mice translate into functional changes, we performed activity assays in cerebellar tissues from 5-week-old WT and Atxn1-KO mice. We first asked whether the alterations in protein changes were due to changes in mitochondria numbers in the cerebellum as indicated by changes in mtDNA copy number. To address this, we quantified the DNA levels of the mitochondrial gene Nd1 relative to the single copy nuclear gene voltage-dependent anion-selective channel protein 1 (Vdac1) by cerebellar DNA qRT-PCR (Supplementary Material, Fig. S1A ). We found no differences in mtDNA levels in the cerebellum from WT and Atxn1-KO mice [F (1, 12) ¼ 0.085, P ¼ 0.776], suggesting that the changes in the metabolic proteome are not due to overall increase in mitochondria number.
The pivotal glycolysis enzyme, PKM was found regulated by ATXN1 at it was increased in the Atxn1-KO mice proteome (Fig. 1B) . To determine whether the increase in PKM-i1 levels resulted in increased activity, we performed functional assays for PKM activity in cerebellar lysates. There are two isoforms of PKM, isoform 1 (i1) and isoform 2 (i2), with the later detected in dividing tissue while the former being the major isoform in non-dividing tissue including brain. Although Pkm isoform 2 (PKM-i2) is highly regulated, PKM-i1 is constitutively active. PKM enzyme is involved in the conversion of phosphoenolpyruvate (PEP) to pyruvate during which adenosine diphosphate (ADP) forms ATP. Pyruvate is then able to form lactic acid through lactate dehydrogenase (LDH) by reducing nicotinamide adenine (NAD) to dinucleotide (NAD)þ hydrogenhydrogen (H) (NADH). The addition of fructose-1, 6-biphosphate (FBP) activates PKM-i2 and allows the detection of the full activity of both isoforms. We determined the relative activity of PKM in the presence and absence of FBP by quantifying the ATP levels after adding PEP using a luciferase-based assay. Also, we measured the change in absorbance at 340 nm, indicative of levels of NADH, after addition of PEP and LDH as an indirect measurement of pyruvate changes due to PKM levels in the Atxn1-KO compared with WT mice (Fig. 3A and B) . In the absence of FBP, there was a 1.7-fold increase in constitutive PKM activity corresponding to PKM-i1 as determined by the ATP assay [F (1, 8) 
Modest but significant increases in the absence of FBP were also detected in the cerebellum of the Atxn1-KO compared with WT mice using the LDH assay [F (1, 8) Fig. 3B ]. However, after addition of FBP, a smaller non-significant difference in the total PKM activity between the WT and KO mice was detected in both the LDH and ATP assays [F (1, 8) 
These data suggest that the proportion of constitutively active PKM-i1 is higher in the Atxn1-KO mice compared with WT mice. Also WT mice may have a slightly higher content of PKM-i2 compared with KO mice since changes in the PKM activity between the WT and KO mice did not reach statistical significance in the presence of FBP. As expected no significant differences were detected in the absence or presence of FBP for the WT mice [ATP assay or LDH assays, respectively: Fig. 3A and B]. However, although not reaching statistical significance, cerebellar lysates of the WT mice have a slightly higher lactic acid production relative to the KO mice (Fig. 3B ). In line with these results, it has previously been reported that PKM-i2 is more active in the conversion of pyruvate to lactic acid compared with PKM-i1 (61) .
As pyruvate enters the mitochondria, it is converted into acetyl-coA by pyruvate dehydrogenase. Oxaloacetate (OAA) together with acetyl-coA then forms citrate through CS, a protein that was found up-regulated in the cerebellum from 5-week-old Atxn1-KO. To test whether the increases in CS activity mirrored the CS level increase detected in the Atxn1-KO mice cerebellum, we performed activity assays following addition of OAA and acetyl-CoA. The reaction was quantified using 5,5
0 -dithiobis-(2-nitrobenzoic acid) (DTNB) which forms 5-thio-2-nitrobenzoic acid (TNB) when it reacts with sulfhydryl groups such as those in the CoA generated in this enzymatic reaction. We found that although increase in levels of CS proteins was verified, no S3C ). Therefore increases in CS protein levels following in the Atxn1-KO mice do not result in increased CS enzymatic activity suggesting that post-translational modifications such as phosphorylation may play an important role in its activity regulation. Because of the detected changes in bioenergetics proteins and activity of glycolysis proteins such as PKM, we asked whether the ATP levels were altered in the cerebellum of the 5-week-old Atxn1-KO mice (Supplementary Material, Fig. S3D ). No significant differences in ATP levels between the WT and Atxn1-KO mice cerebellar lysate were detected (N ¼ 6 each, Games-Howell, P ¼ 0.96). Overall, this suggests that the increases in the identified key proteins of bioenergetics pathways identified in the Atxn1-KO mice by proteomic analysis may be a compensatory response to maintain ATP levels.
ATXN1 loss of function induces changes in the mitochondria electron transport chain activity
To examine if there were defects in the oxidative phosphorylation system in the Atxn1-KO cerebellum that may underlie the up-regulation of the bioenergetics proteome, we determined the activity of different electron transport chain (ETC) complex activities (Fig. 3C ). The activity of complex II, containing SDHA, was found increased, by over 30% [F (1,4) ¼ 7.443, P ¼ 0.05] mirroring the proteome change detected, while a significant decrease (50%) in activity in complex I was detected [F (1, 4) 
Similarly to complex II, complex III showed a statistically significant increase (1.5-fold) in activity (Mann-Whitney U Test, P ¼ 0.021). On the other hand, no activity change was detected on Complex IV [F (1, 6) 
In addition, we compared the transport of electrons from complexes I to III and from complexes II to III. We detected a slight decrease in activity in complexes I-III [F (1,6) ¼ 5.11216, P ¼ 0.064] that did not reach statistical significance probably due to some compensation from both the increased complexes II and III activity (Fig. 3C) . On the other hand, the electron transfer from complexes II to III was significantly increased since the activity of each of these complexes was found enhanced in the Atxn1-KO 5-week-old mice cerebellum (Fig. 3C , Mann-Whitney U Test: P ¼ 0.04). These results suggest that the decrease in complex I is compensated by increases in complexes II and III (Fig. 3C ).
Bioenergetics proteome is altered in the 5-week-old SCA1 mouse cerebellum
To determine whether the ATXN1-regulated proteome is altered in the cerebellum of the 5-week-old SCA1 mice model (B05), prior to the outward presentation of symptoms, we analysed lysates from WT mice, WT ATXN1 over-expressing mice (A02) and SCA1 (B05) mice expressing mutant ATXN1[82Q] (Fig. 4A and B and Supplementary Material, Fig. S2 ). We found that levels of CS, GPD2 and SDHA were similar in SCA1 (B05) and the WT mice cerebellum. In contrast, levels were reduced in the SCA1 mice (B05) cerebellum by 60% for ATP5H, and around 30% for PKM-i1, PRDX6 and PSA6 compared with the WT mice and WT ATXN1 over-expressing A02 mice (Tukey HSD (honest significant To determine whether the changes in the bioenergetics proteome may have resulted from changes in mitochondria levels, we quantified the relative amount of mtDNA relative to the nuclear DNA by performing qRT-PCR from the mtDNA Nd1 gene of the cerebellum of SCA1 transgenic mice (B05) as previously shown for Atxn1-KO mice. No significant change in mtDNA copy levels in the SCA1 (B05) compared with WT mice were identified (Supplementary Material, Fig. S5A and S5B ). Therefore the changes in mitochondria and other bioenergetics related proteins in the SCA1 cerebellum do not appear to reflect a change in mitochondria numbers. Next, we examined whether expression of mutant ATXN1 had an effect on ATP levels in the 5-week-old mouse cerebellum. We first determined the levels of ATP in the cerebellum of mice expressing WT (A02) or mutant ATXN1 (SCA1 B05) compared with WT background strain C57BL/ 6J mice ATP levels were found significantly lower in the cerebellum of the SCA1 B05 mice (50%) compared with WT or A02 mice ( This suggests that the decrease in the ATP levels is an early event prior to morphological changes indicative of cell death although concurrent with neurite alterations previously shown (13) .
Dysregulation of the mitochondria ETC complex activity in the SCA1 mouse cerebellum
Unlike the Atxn1-KO mice, SDHA levels appeared unchanged in the 5-week-old SCA1 mice (B05). However, we went on to determine whether there were defects in the activity of other ETC complexes which may account for the ATP level decreases detected in the SCA1 mice (Fig. 4E ). Significant differences were only noted in levels of the complex III activity, which was decreased around 50% in the B05 mice cerebellum compared with WT mice [F (1,6) ¼ 37.06, P ¼ 0.00089]. This change in complex III activity was opposite to what is detected in the Atxn1-KO cerebellum where a significant increase was noted (Fig. 3C) . Complex III is a critical component of the ETC chain as it can accept electrons from either complex II or I. At the same time, it releases two hydrogen ions into the mitochondrial intermembrane space contributing to the ion gradient needed for ATP synthesis. Interestingly, complex I activity appears slightly increased although it did not reach statistical significance [F (1, 4) Changes in GSK3b and mTOR activation state are indicative of a role of ATXN1 in the regulation of nutrient sensing and metabolism Although loss of function reveals the ATXN1-mediated proteome changes, it does not explain the effects of the mutant ATXN1 on the expression of metabolic proteins as represented in Figures 2  and 4 . ATP level sensing mechanisms mediate the activation of pathways that control the expression of proteins involved in bioenergetics or activate catabolic pathways in the case of starvation due to low ATP levels (62) (63) (64) . Therefore to determine whether two major proteins involved in nutrient or energy sensing are altered by ATXN1 loss of function or the expression of the mutant form of ATXN1, we quantified the levels of phospho-GSK3b (ser9), which identifies the inactive form of GSK3b and phospho-mTOR (ser2448) the active form of mTOR. In support of ATXN1 roles in cellular metabolism, we found that it regulates the glycogen synthesis and mTOR regulator, GSK3b. In fact we previously showed that ATXN1 regulates the phosphorylation levels of ser9 in GSK3b, which are indicative of its activation state (13) . Specifically, we previously showed that an increased proportion of the total GSK3b in the cerebellum of Atxn1-KO mice had the inhibitory phosphorylation in the ser9 indicative of lower activity and known to be regulated by PP2A (13) . Here, we determined the total levels of p-GSK3b (ser9) and mTOR phosphorylated at ser2448 [p-mTOR (ser2448)] in the 5-week-old mice cerebellum. The values were normalized to actin, which indicate total levels of active GSK3b which would have a direct effect on bioenergetics ( Fig. 5A and B) . In the Atxn1-KO mice, we found levels of p-GSK3b (ser9) significantly higher than in WT mice and thus less active [1.5-fold, F (1,10) ¼ 9.56979, P ¼ 0.011, Fig. 5A ]. In the cerebellum of the A02 mice over-expressing WT ATXN1, the p-GSK3b (ser9) levels are similar to that in WT mice indicating that increases in ATXN1 beyond WT levels is not sufficient to induce altered levels of active GSK3b (Fig. 5) . However, in the cerebellum of the mutant ATXN1 expressing SCA1 mice (B05), the levels of p-GSK3b (ser9) are significantly lower compared with WT (57%; [F (1,9) ¼ 5.95795, P ¼ 0.037] or to A02 [F (1, 8) ¼ 6.79, P ¼ 0.031] indicative of higher levels of activated GSK3b (Fig. 5A) . mTOR, another signalling protein involved in energy sensing and related homeostasis pathways such as autophagy and protein synthesis, is also altered in the cerebellum of the Atxn1-KO and in the mutant SCA1 mouse (Fig.  5B) . The levels of phospho-mTOR at the serine 2448 [p-mTOR (ser2448)], indicative of activation, decrease slightly but not significantly in the Atxn1-KO [F (1,6) ¼ 4.09, P ¼ 0.089] while the SCA1 mice (B05) exhibit a significant decrease in p-TOR (ser2448) levels [WT versus B05: F (1,6) ¼ 80.005, P ¼ 0.010]. However, the levels of p-mTOR(ser2448) did not differ in the mice over-expressing the WT ATXN1 (A02) compared with WT mice [ Fig. 5B ; WT versus A02: F (1,7) ¼ 0.900, P ¼ 0.374]. Therefore, loss of ATXN1 functions is not be sufficient to explain the mutation induced decrease in active pmTOR (ser2448) levels in the SCA1 mouse model (Fig. 5A and B) .
ATXN1-regulation of ATP5H, PKM-i1 and ATP levels involves GSK3b and mTOR pathways
To test whether dysregulation of GSK3b and mTOR together contribute to the alterations in the expression of the Figure 5C and D, respectively. (E) Representative western blots from the samples described in Figure 5C and D. (F) ATP levels were determined from lysates of transfected cell samples described in Figure 5C and D and represented as relative units. Experiment was performed in duplicate. One-way ANOVA was used to test for statistical significance. *P 0.05, **P 0.005. Error bars denote SEM.
ATXN1-regulated bioenergetics proteins such as ATP5H and PKM-i1, we treated a cell culture model of SCA1 transiently expressing WT ATXN1[30Q]) or mutant ATXN1[80Q] with the GSK3b inhibitor, Tideglusib (2.5 mM) and/or with the mTOR activator, MHY1485 (2.5 mM). As also detected in the cerebellum from 5-week-old SCA1 mice (Fig. 4) 
We further tested the effects of the GSK3b and mTOR modulators on ATP levels in the cultured cells expressing WT ATXN1[30Q] or ATXN1[80Q] (Fig. 5F ). As previously shown in Figure 4D , ATP levels decrease in the mutant ATXN1 expressing cells and a slight but significant increase in the WT ATXN1 over-expressing cells was detected [ 
Discussion
The aim of this study was to uncover molecular pathways affected by ATXN1 loss of function in the mouse cerebellum and to determine the effect of the mutation on these functions of ATXN1 in the cerebellum of a SCA1 mouse model. For this purpose, we performed an unbiased proteomic study to identify the ATXN1-regulated cerebellar proteome. Analysis of the proteins that are differentially expressed in Atxn1-KO mice revealed an important contribution of ATXN1 in the early metabolic regulation of the cerebellum as most of the proteins clustered around bioenergetics metabolic functions. The altered proteome in Atxn1-KO mice include proteins involved in glycolysis (PKM-i1, ENO1, GPI), the TCA cycle (Cs) and ETC chain (SDHA, ATP5H). The rest of the identified proteins regulated by ATXN1 have metabolic functions related to detoxification from reactive side products such as hydrogen peroxide (PRDX6) and aldehydes (ALDH1A1, ALDH1L1) in addition to protein degradation (PSA6) (Fig. 1) . Aldehydes and free radicals can diffuse through cell membranes and form adducts such as 4-hydroxynonedal (4HNE) with lipids, DNA and proteins. Increases in reactive oxygen species, oxidative stress damage and defective protein degradation, have been previously reported throughout animal models of neurodegeneration and among patients (44, 65, 66) . The decrease in PRDX6 and PSA6 proteins in the cerebellum of the 5-week-old SCA1 mice may further contribute to altered protein homeostasis, including oxidative damage to DNA and proteins and the accumulation of defective proteins.
The ATXN1-mediated proteome regulation could be partly explained by its role as a transcriptional co-factor. In addition to changes in the Atp5a1 mRNA, previously found transcriptionally regulated by Atxn1 using microarray analysis (10), we found that the mRNA of Aldh1a1, Cs, Gpi and Pkm-i1 were up-regulated in the Atxn1-KO mice (Fig. 2) . This result indicates that in the cerebellum, ATXN1 may function as a suppressor of Aldh1a1, Cs, Gpi and Pkm-i1 transcription, so that in the absence of ATXN1 their levels are increased. ATXN1 has previously been shown to function as a transcriptional co-regulator of capicua, HMG, Retinoic acid receptor-related orphan receptor alpha (RORa) and Sp1 among others (10, 59, 67) . Aldh1a1 promoter contains retinoic acid receptor alpha/ retinoid x receptor alpha (RARa/RXRa) and Sp1 sites, while both Cs and Gpi contained RORa but no Sp1 sites. In fact, in the mouse cerebellum, Cs transcription is modulated by the ATXN1-RORa binding and this was previously shown altered in SCA1 (27, 68) . On the other hand, ATXN1 functions as a co-transcriptional factor for Sp1 (10) supports its role in the transcriptional regulation of Pkm, which contains Sp1 and Sp3 GC-boxes binding-sites. Sp1/Sp3 sites play a role in glucose-mediated stimulation of Pkm gene transcription (69) . However, it should be noted that Pkm-i1 is a product of differential splicing and the expression of the specific isoforms requires heterogeneous nuclear ribonucleoproteins, which adds another level of regulation. Although the data support the ATXN1 mediated regulation of PKM-i1 at the transcriptional level, we cannot discard the possibility that it may involve differential splicing since the primer chosen for the qRT-PCR is at the PKM-i1 specific region exon 9 (Fig. 2) . However, we found that not all the components of the same functional proteome clusters were regulated at the transcriptional level. This indicates that in addition to its function as transcriptional co-factor other functions of ATXN1 are involved in the resulting proteome involving post-transcriptional regulation.
The pyruvate kinase (PKM) is known to be a critical enzyme for the process of glucose breakdown into intermediates that are further used during oxidative phosphorylation for the more efficient synthesis of ATP. Four pyruvate kinase (PK) isoforms are known, but PKM-i2 is the only one allosterically regulated by FBP and induces tetramerization upon binding. The PKM-i2 dimer leads to an increased lactate production while the active PKM-i2 tetramer produces pyruvate for oxidative phosphorylation. PKM-i1 on the other hand does not require FBP to form tetramers and replacing PKM-i2 with PKM-i1 leads to an increase in pyruvate and decrease in lactate. Although PKM-i2 is the abundant isoform in mitotic tissue, the PKM-i1 is the major isoform expressed in non-dividing cells such as in brain. We found that the PKM-i1 levels were increased in the cerebellum of the 5-week-old ATXN1-KO mice (Figs 1 and 2 ) and that this protein increase is also mirrored in activity levels (Fig. 3) . This increased activity yields more of the substrate, pyruvate, for entrance into the TCA cycle as also supported by the LDH assay. In fact, CS which reacts with the two-carbon acetate residue from acetyl coenzyme A and a molecule of four-carbon OAA to form the sixcarbon citrate, was also increased in the Atxn1-KO, although no significant changes were noted in the activity ( Supplementary  Material, Fig. S3C ). It has previously been proposed that the activity of CS may be post-traslationally regulated by phosphorylation-dephosphorylating cycles although the kinases and phosphatase involved have not been clearly shown (70) . In this regard, the regulation of PP2A phosphatase by ATXN1 may be involved in the CS deregulation in the Atxn1-KO and SCA1 mouse model (13) . However, further work would be needed to test whether ATXN1-regulated PP2A is involved in the regulation of CS specific activity.
In addition to yielding electron donors such as NADH and succinate, the TCA cycle also serves to replenish the neurotransmitter glutamate from the transamination of a-ketoglutarate or glutamine hydrolysis. Glutamate, in turn can be further decarboxylated to yield gamma-aminobutyric acid (GABA). another critical neurotransmitter for cerebellar functions (Fig. 6) . Therefore, this metabolic machinery is of outmost importance for the generation of ATP and also for the proper cerebellar circuitry. The up-regulation of components of both the glycolysis and TCA cycle may result from either defective production of ATP or an enhanced requirement of the cells for increased ATP and/or neurotransmitter signalling. Therefore, we analysed ATP levels in the cerebellum of the 5-week-old Atxn1-KO mice and found no differences in ATP levels compared with WT mice (Supplementary Material, Fig. S3D ). Therefore in the Atxn1-KO mice, there appears to be enhanced glycolysis and pyruvate synthesis as well as increases in two proteins of the ETC (SDHA and ATP5H) chain with no resulting ATP level changes. Interestingly, enhanced resting metabolism accompanied by weight loss was previously described in SCA1 patients (41, 65) . The increase in many of the metabolic proteins due to ATXN1 loss of function may be the result of a release from ATXN1 mediated suppression or indirectly as an induced compensatory mechanism due to faulty bioenergetics involving the ETC functions. For instance, the decrease in PKM-i1 detected in the SCA1 cerebellum would result in lower levels of pyruvate which is needed for oxalate and malate synthesis, reactions which yield the complex I required electron donor, NADH. Furthermore, in addition to regulation of pyruvate levels, PKM is a transcriptional co-factor regulation involved in the regulation of different genes including VEGFA, previously found down-regulated in the SCA1 mouse model (71, 72) .
The ETC consists of four multiprotein complexes that mediate the electron transfer from NADH and succinate to the electron acceptor O 2 . Therefore, we tested whether there were deficits in the activity of ETC components that may account for the enhanced metabolic proteome induced by the lack of ATXN1 with no resulting increase in ATP levels (Figs 3 and 6 ). Complexes I and II accept the electrons from NADH and the reduced flavin adenine dinucleotide (FADH2) respectively, which are synthesized during the TCA cycle. Both of these complexes are able to donate electrons to complex III, while pumping hydrogen ions across to the mitochondria inner membrane thus creating an ion gradient critical for ATP synthesis. We found that complex I activity was decreased over 50% in mitochondria isolated from the cerebellum of the 5-week-old Atxn1-KO compared with WT mice (Fig. 3) . On the other hand, as expected, the complex II activity was increased by over 50% in the Atxn1-KO mice mirroring the increase in the ATXN1-regulated proteome of the complex II protein SDHA (Fig. 2) . Interestingly, an increase in the complex III activity of over 1.5-fold was also detected. Because the Atxn1-KO mice have lower levels of GPD2, involved in restoring the FADH2 from flavin adenine dinucleotide (FAD) the electron donor for the complex II may be limited. Therefore, the increases in SDHA levels may be due to a compensatory mechanism. Likewise when measuring the activity from complexes I to III, no change was detected although complex I activity is decreased due to the upregulation of complex III activity. On the other hand, increases in complexes II-III activity were detected given the increases in complexes II and III activities identified in the Atxn1 KO mice (Fig.  3) . Thus, the decrease in complex I activity, the limited electron donor for complex II, even considering the increase in complexes II and III activity, leads to no net ATP level changes.
The Atp5h gene encodes the ATP synthase, Hþ transporting mitochondrial F 0 complex subunit d, part of the F 0 ion channel subunit of the ETC complex V. ATP5H is embedded in the intron 3 of another gene encoding a potassium channel KCTD2 gene. Interestingly, this ATP5H/KCTD2 locus has been recently linked to AD (73) . Mutations in ATP6, another mtDNA encoded component of the mitochondrial complex V cause ataxia and maternally inherited Leigh (OMIM #256000). Mutations in the complex V ATP5A1 (OMIM# 164360) causes mitochondrial complex V (ATP Synthase) deficiency nuclear type 4 (1 family) with a variant in both alleles of ATP5A1 causing a deficiency in the subunit 5 and progressive encephalopathy and early infancy death (74) . Although the effect of changes in the levels of ATP5H is not known, that the expression of another component of the ETC complex V was also found dysregulated in the Atxn1-KO mice suggests that there may be an up-regulation of ATP synthase activity potentially to sustain normal ATP level synthesis.
In contrast to what is observed in the Atxn1-KO mice, the cerebellum of the 5-week-old SCA1 mice exhibited decreased levels of ATP5H, PKM-i1, PRDX6 and PSA6 but no changes in CS or GPD2 (Fig. 5A ). In addition, the ATP levels in the SCA1 B05 mice expressing the mutant ATXN1 and cells expressing the mutant ATXN1 (ATXN1[80Q]) were decreased by around 30% compared with WT mice (Fig. 4C and D) . We further tested the activity of the ETC complexes and found no statistically significant changes in complex I or II. However, there were significant decreases in complex III activity ($50%), also reflected in the complexes II-III activity assay (Fig. 4E) . The decrease in PKM-i1 levels and the consequent decrease in pyruvate compared with WT mice, together with the statistically significant defect in complex III activity and the lower ATP5H, may account for the decrease in ATP levels following expression of the mutant ATXN1 in the mice (B05) or cellular SCA1 models. This decrease in complex III is of special interest since SCA1 patients present neuropathy mostly of the axonal type and involving both sensory and motor fibres. Furthermore, neurological conditions caused by mitochondrial complex III deficiency due to mutations in core complex III proteins present ataxia in addition to neuropathy among other symptoms (75) (76) (77) .
Given that many of the proteins involved in bioenergetics Atxn1-KO are increased, we propose that ATXN1 appears to down-regulate their expression. Therefore, we reasoned that over-expressing ATXN1 (A02 mice) would result in levels similar or lower to those in WT mice. In the case of GPD2, for which loss of ATXN1 results in its increase its expression, we expected over-expression of ATXN1 to bring its levels higher or similar to WT. As expected, levels of the proteins involved in bioenergetics (ATP5H, CS, PKM-i1, GPD2 and SDHA) were similar to those of WT levels (Fig. 4A) . Interestingly, dysregulation of ATXN1 levels either in the Atxn1-KO or in the over-expressing transgenic (A02) seems to induce PRDX6 and PSA6 expression, suggesting that the changes in these proteins may be due to a stress response rather than a direct effect of ATXN1 protein per se.
We previously found that ATXN1 regulated the expression of two modulators of PP2A activity, PP2B beta and ANP32A, a regulatory subunit and endogenous inhibitor of PP2A, respectively (13) . In addition, we found that the inhibiting phospho-ser9 site of GSK3b (p-GSK3b) and the activating phospho-T185/Y187 ERK2 site, known to be PP2A substrates, were regulated by ATXN1 (13) . Both GSK3b and ERK2 regulate Tuberin (TSC2) which forms a complex with Hamartin (TSC1) thus modulating the mTOR complex 1 (mTORC1) signalling which regulates the nutrientinduced activation of mRNA translation through phosphorylation of S6K1 and EIF4E-BP1 and mTOR complex 2 (mTORC2) (78). Although ERK2 has been shown to inhibit TSC2, GSK3b activates it, thus having opposite effects on protein synthesis, autophagy and mitochondrial biogenesis (79) . Although the TSC1/TSC2 activates mTORC1, it represses mTORC2 which has a feedbackloop regulatory effect on itself and mTORC1 through the regulation of AKT473 phoshoepitope (80) . Therefore mTORC2 also plays an important role in mTORC1 regulation since active p-AKT473 inhibits the TSC1 thereby releasing the inhibition on the activator of mTORC1, Ras homolog enriched in brain (RHEB). The critical role of mTORC1 and mTORC2 in PCs is also supported by data on the chronic inhibition of either mTORC1 or mTORC2 modelled in the mouse knockouts of raptor and rictor showing age-dependent PC loss and motor deficits (81) . The Atxn1-KO which expresses higher levels of active ERK2 and low active GSK3b compared with WT mice, we would have more inhibition of TSC2, thus resulting in more mTORC1 and less mTORC2 activity (13) (Fig. 6A) . On the other hand, expression of the mutant ATXN1 induces opposite effects, decreases in ERK2 and increases GSK3b activity leading to decreased mTORC1 and increased mTORC2 activation (80) . However, because the mutant ATXN1 also induces decreases in mTOR ser-2448 phosphorylation indicative of low activation state, the mTORC2 activity would not increase as expected and the inhibition of mTOR1 would be enhanced (Fig. 6B) . Therefore, while in the Atxn1-KO mice the mTORC1 would be more active, the expression of the mutant ATXN1 in SCA1 supresses both mTORC1 and mTORC2 activity.
We then reasoned that the ATXN1 regulation of GSK3b might be upstream of many of the bioenergetics proteome changes identified here because both transcription and translation seemed involved in the proteome changes detected. ATXN1 has been shown to regulate GSK3b through PP2A. GSK3b, upstream regulator of mTOR, is a well-known modulator of metabolism (13) . In addition to its critical role in translation through mTOR, GSK3b is a known transcriptional regulator through phosphorylation of transcription factors such as cAMP response element-binding (CREB) and has been shown to regulate the expression of mitochondria proteins through interaction with the transcriptional factor YY1 (82) . In fact, we found that the cerebellum of the Atxn1-KO mice contained higher levels of p-GSK3b (ser9) (1.5-fold) thus less active GSK3b, and no changes in active mTOR compared with WT mice. On the other hand, the p-GSK3b (ser9) phosphoepitope was decreased (57%) in the SCA1 mice, thus containing more active GSK3b and less active mTOR (Fig. 5A and B) . Taken together these data suggest that in the 5-week-old Atxn1-KO mice cerebellum the lower levels of active GSK3b, would result in higher levels of mTORC1 compared with WT mice. In contrast, the cerebellum of the 5-week-old SCA1 (B05) mice contains higher levels of GSK3b activity and lower levels of active mTOR resulting in higher suppression of mTORC1 and more activation of the mTORC 2 complex (Fig. 6) . However, because low levels of active mTOR were also found in the SCA1 (B05) mice, no increase in mTORC2 complex compared with WT mice would be expected. In addition, STRING multiprotein network analysis of the ATXN1-regulated proteome against either mouse or human background shows interaction of both GSK3b and mTOR only through PKM (Supplementary Material, Tables S8 and S10). GSK3b can physically interact with PKM and mTOR has been shown to regulate the expression of PKM at the transcriptional level through HIF1-alpha (64) . These data suggested the GSK3b-mTOR signalling in mediating the ATXN1 mutation-induced alterations on the ATXN1-regulated proteome. To begin test, we used chemical modulators of the GSK3b (Tideglusib) and mTOR activity (MHY1485) to determine whether decreasing the activity of GSK3b, increasing the mTOR activity or both, would restore WT levels of the ATXN1-regulated proteome and also ATP levels ( Fig. 5C-F) . We focused on the effects on PKM-i1 and ATP5H levels because these are altered in the cerebellum of the SCA1 (B05) mice and cell model and are regulated at the transcriptional and post-transcriptional level, respectively (Figs 2 and 4A) . Also PKM-i1 and ATP5H are involved in two key energy metabolism pathways, TCA cycle and oxidative phosphorylation. We found that expression of mutant ATXN1 (ATXN1[80Q]) but not WT ATXN1 (ATXN1[30Q] ) in SH-SY5Y cells results in significant decreases in levels of both PKM-i1 and ATP5H (Fig. 5A and B) as was detected in the SCA1 (B05) transgenic mouse model (Fig. 4A) . Treatment with either Tideglusib to lower GSK3b activity or with MHY1485 to increase mTOR activity or both together induced PKM-i1 levels similar to those in cells over-expressing exogenous ATXN1[30Q] or the endogenous WT ATXN1. However, treatment with both compounds together gave similar results with less variability (Fig. 5A) . In contrast, treatment with both, Tideglusib and MHY1485 was required by ATXN1[80Q] expressing cells to express ATP5H to similar levels than those in cells expressing endogenous (empty vector) WT ATXN1 (Fig. 5B) . Interestingly, the ATP5H levels in the WT ATXN1[30Q] over-expressing cells was enhanced after MHY1485 treatment in line with the finding that these cells and the transgenic mice over-expressing WT ATXN1 (A02) show higher levels of mTOR activity (Fig. 5B) .
That the Atxn1-KO mice cerebellum contains higher levels of p-GSK3b thus lower levels of active GSK3b and ATP5H and PKMi1 levels are increased compared with WT mice, suggest that ATXN1 may keep the levels of these proteins suppressed to WT levels through mechanisms involving mTORC1. Furthermore, we propose that the expression of the mutant ATXN1 in the cerebellum from SCA1 mice induces an increase in active GSK3b and lower levels of active mTOR. This may then result in decreases in both mTORC1 and mTORC2 activities, and an enhanced suppression of the bioenergetics proteins ATP5H, PKMi1 beyond WT levels. That mTORC1 appears to be a critical complex involved in the ATXN1-mediated regulation of PKM-i1 and ATP5H levels is supported by the fact that both, the activation of mTOR in the SCA1 cell model by MHY1485 which favours the activation of mTORC2 and the inhibitor of the GSK3b (Tideglusib) alone, which would decrease mTORC2 activity, were able to bring PKM-i1 to WT levels. In both cases, a small increase in mTORC1 is expected, with mTOR activation slightly increasing the active proportion of the mTORC1 and with the inhibition of GSK3b lifting the inhibition of the activator of mTORC1, RHEB. Furthermore, ATP5H appear to require both the inhibition of GSK3b and the activation of mTOR, which would favour the increase in mTORC1. The effects of these compounds on ATP levels were very similar to those on the PKM-i1 and ATP5H (Fig. 5F ). Although either inhibition of GSK3b (Tideglusib) and activation of mTOR (MHY1485) induced a slight increase in ATP levels in the ATXN1[80Q] expressing cells, the combination of both modulators significantly increased ATP levels similar to those of WT ATXN1 expressing cells. Therefore, activation of mTORC1, albeit at different levels, appears to mediate the ATXN1-regulated bioenergetics proteome and ATP levels. Furthermore, inhibiting or down-regulating GSK3b activity may be sufficient to release the inhibition of mTORC1 but the low activation state of mTOR in SCA1 would prevent the activation of the complex. This may explain why treatment with lithium, the non-specific inhibitor of GSK3b, was unable to effectively inhibit the symptoms although it did have an ameliorating effect on both motor and the metabolomics profile of SCA1 mouse models and patients (44) .
A recent study also supports some of our conclusions on the dysregulation of mTORC1 in a SCA1-KI (83) . The study demonstrates a role for Homer-3, also previously shown to be altered in the B05 SCA1 model, in the motor symptoms of the SCA1-KI mouse and show that the expression of homer-3 is dependent on mTORC1. Interestingly, neuronal synaptic activity is restored by exogenous expression of homer-3 or addition of agonists of mGlutR1. However, the neuronal activation by the agonist treatment but not by expression of homer-3 is abnormal in the SCA1, suggesting that homer-3 is downstream of the receptormediated effects and that mTORC1 dysregulation is upstream of homer-3 decrease. Most recently a very interesting article has just been published analysing the transcriptome of the ATXN1[82Q] B05 SCA1 mice and a transgenic mice expressing the WT ATXN1[30Q] with the D776 mutation mimicking the phosphosite linked to severe ataxia (84) . In contrast to the ATXN1[82Q] B05 SCA1 mice, the ATXN1[30Q]D776 mice show ataxia without PC death. They show that cholecystokinin (CCK1) is a differentially up-regulated transcript in ATXN1[30Q]-D776 and that signalling through the CCK1 receptor can induce the neuroprotective effects responsible for the lack of purkinje pathology progression in this mice model (84) . Here, we found evidence supporting a role for ATXN1 as an upstream modulator of mTORC1 through both GSK3b and mTOR. Furthermore, that the GSK3b-mTOR pathway is dysregulated in the B05 SCA1 mice may underlie the transcriptional and translational dysregulation downstream targets including proteins involved in synaptic activity such as homer-3 in addition to the energy homeostasis proteins. Notably, the CCK1R signalling can also activate the mTOR pathway through phosphoinositide-3-kinases (PI3K).
Here, we provide evidence for a role of ATXN1 in the regulation of metabolism and bioenergetics through the modulation of the levels of key enzymatic components. Also, we found that the expanded polyglutamine mutation in the ATXN1 protein enhances its suppression function on PKM-i1, PRDX6, ATP5H and PSA6 expression and the ETC complex III activity. We also show that ATXN1 has profound effects on the levels of the active forms of GSK3b and mTOR. Pharmacological studies shown suggest that these master proteins are upstream from the ATXN1-regulated proteome changes and its effects on ATP levels. Much work is still needed to elucidate the specific mechanisms by which ATXN1 regulates each of these bioenergetics components. However, here we propose that the alterations in ATXN1 functions in the regulation of mTOR and its regulatory roles on GSK3b activity mediate the transcriptional and posttranscriptional changes in energy metabolic pathways that are affected in SCA1. Taken together these data also suggest that a combinatorial therapeutic approach may be useful to restore the normal activity levels of GSK3b and mTOR to prevent the identified metabolic dysregulation in SCA1 and possibly other neurological conditions involving ATXN1.
Materials and Methods
Mice
Five-week-old inbred Atxn1-null (Atxn1-KO À/À ) and transgenic mice carrying the mutant SCA1 allele with 82 repeats (B05) or an interrupted WT SCA1 allele with 30 repeats (A02) driving the expression in cerebellar PCs of mutant or WT ATXN1 containing 82 or 30 glutamines, respectively, were previously described elsewhere (25, 85) . All animal procedures were performed in accordance with the European Community Council Directive and local regulations and approved by appropriate Institutional Ethics Committees.
Two-dimensional fluorescence differential in gel electrophoresis
Cerebellar protein lysates from 5-week-old male inbred C57Bl/6J WT and Atxn1-KO mice (N ¼ 6/group) and a pool with equal amount of protein from each sample were analysed by 2D-DIGE. Frozen samples were homogenized in cold DIGE lysis buffer (7 M urea, 2 M thiourea, 4% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 30 mM Tris, pH 8.5), for protein extraction. After homogenization with a glass douncer and centrifugation at 12 000 g for 5 min at 4 C, the cleared protein extract was further purified by a modified trichloroacetic acid-acetone precipitation (2-D-CleanUp kit, GE Healthcare) and re-dissolved in DIGE lysis buffer. Protein concentration was determined using the BioRad RC-DC Protein Assay (Bio-Rad). For intragel and intergel quantitative normalizations, an internal standard was prepared by pooling an aliquot of each biological sample (6 WT and 6 KO) in the experiment. Labelling was performed with 400 pmol of each CyDye DIGE Fluor Cy3 and Cy5 minimal dyes (GE Healthcare) in 1 ll of anhydrous N,N-dimethylformamide per 50 mg of protein following the manufacturer's instructions. The internal standard sample was labelled with CyDye DIGE Fluor Cy2 minimal dye.
After incubation for 30 min on ice in the dark, the labelling reactions were quenched with 10 mM lysine and incubated for 15 min on ice in the dark. To compare the expression profiles from 5-week-old inbred C57Bl/6J WT (N ¼ 6) and Atxn1-KO (N ¼ 6) mice, six 2D-DIGE gels were run in parallel, each one including the internal standard sample. To eliminate any possible effect of the labelling intensity on the quantitation the dye labelling of the KO and WT samples (each labelled with Cy3 ¼ 3 gels and Cy5 ¼ 3 gels) were alternated. The internal control containing the pooled samples was labelled with Cy2 and included in every gel together with the WT and KO samples. Fifty micrograms of protein per CyDye labelled sample (150 mg of total protein) were pooled and diluted 2-fold with isoelectric focusing (IEF) sample buffer containing 7 M urea, 2 M thiourea, 4% CHAPS, 2% Dithiothreitol (DTT), 0.002% bromophenol blue and 2% Immobilized pH gradient (IPG) Buffer pH 3-10 (GE Healthcare). The IEF was performed as per manufacturers instructions using IPG strips (24 cm, linear gradient, pH 3-10, GE Healthcare) and an Ettan IPGphor IEF System (GE Healthcare). The strips were focused at 65 kVh in a multistep program that consisted of 300 V step and hold for 3 h at 1000 V gradient for 6 h; 8000 V gradient for 3 h; 8000 V Step and hold for 5 h 40 min and a final security step at 50 V. After electrofocusing, IPG strips were equilibrated first for 15 min in reducing solution (100 mM Tris pH 8.0, 6 M urea, 30% glycerol, 2% SDS, 0.002% bromophenol blue with 0.5% DTT) and then for 15 min in alkylating solution (100 mM Tris pH 8.0, 6 M urea, 30% glycerol, 2% SDS, 0.002% bromophenol blue with 2.25% iodoacetamide) with gently agitation at RT. The second dimension SDS-PAGE was run in an Ettan DALT-six electrophoresis system (GE Healthcare), by overlaying the strips on 12.5% acrylamide/bisacrylamide (37.5:1) gels (25.5 Â 21 cm) casted on low autofluorescence glass plates. All six gels were run simultaneously at constant 2.5 W/gel for 30 min and 17 W/gel until the bromophenol blue dye front reached the bottom of the gel at 20 C. The precision plus protein standards (Bio-Rad) were run simultaneously in each gel to estimate protein size. 
2D-DIGE gel image and statistical analysis
Mass spectroscopy and protein database search
Identified protein spots of interest were excised with an Ettan Spot Picker (GE Healthcare) following the manufacturer's instructions. Protein spots of interest were excised from the gel by using an automated Spot Picker (GE Healthcare). In-gel trypsin digestion was performed using autolysis-stabilized trypsin (Promega). Tryptic digests were purified using ZipTip microtiter plates (Millipore). MALDI-TOF mass spectroscopy (MS) analysis of tryptic peptides was performed on an Ultraflex TOF-TOF Instrument (Bruker, Bremen, Germany). Samples were prepared using Prespotted AnchorChip (PAC96) target with alpha-cyano-4-hydroxycinnamic acid matrix for 96 sample spots and 24 calibration spots (Bruker Daltonics). The spectra were processed using Flex Analysis 3.2 software (Bruker Daltonics). Identification of proteins was carried out by peptide-mass fingerprinting data from MALDI-TOF MS with the Swiss-Prot protein database using the MASCOT Search engine (Matrix Science, http://www.matrixs cience.com, last accessed May 2015) using the following parameters: taxonomy, Mus musculus; enzyme, trypsin and allowing one missed cleavage. Liquid chromatography-tandem MS (LC-MS/MS) with an Electrospray ionization (ESI)-MS/MS spectrometer and ionic trap (BRUKER Esquire HCT) was performed when peptide sequence was required for identification.
Interaction, GO annotation and enrichment analysis
The database for annotation, visualization and integrated discovery (DAVID Bioinformatics Resources 6.7; http://david.abcc. ncifcrf.gov) (87,88) was used to annotate the genes encoding the ATXN1-regulated proteins and to determine the enrichment of functional categories annotated by the Gene Ontology (GO) terms. For the functional enrichment analysis, the proportion of the identified annotated genes relative to the whole genome annotated genes of the Mus musculus WT mice for each functional category was tested statistically using the Fisher's exact test. Functional categories were assumed significantly enriched at P < 0.05. The identified ATXN1-regulated proteins were functionally analysed using statistical overrepresentation test with the PANTHER classification system based on evolutionarily and functionally related proteins (89, 90) . Protein-protein functional network interaction multi-protein analysis was performed using the STRING database (91) . This analysis is based on physical and functional, experimentally determined and predicted PPIs.
The FDR q 0.05 was set as significance threshold for all determinations.
SDS-PAGE and immunoblotting
Proteins were extracted from mouse cerebella or cultured cells by homogenization in hypotonic lysis buffer: 10 mM Hepes, 10 mM KCl, 2 mM ethylene glycol-bis(b-aminoethyl ether)-N,N,N 0 ,N 0 -tetraacetic acid (EGTA), 320 mM sucrose, 5 mM MgCl2, 1 mM DTT, 25 mM sodium fluoride (NaF), 2.5 mM NaVO 3 and protein inhibitor cocktail (Roche). Protein concentration was determined using the DC-BioRad protein assay (BioRad), and samples were mixed 1:1 with 2X DIGE lysis buffer (14 M urea, 4 M thiourea, 8% CHAPS, 60 mM Tris, pH 8.5). Thirty milligrams of protein samples were mixed with 2X SDS-sample buffer (625 mm Tris pH 6.8, 10% SDS, 50% glycerol, 1 mM DTT and 0.05% bromophenol blue) and separated by electrophoresis at constant 20 mA before transfer to PVDF membranes with an iblot (Life technologies) (13) . Primary antibodies used were GAPDH (G9545, Sigma-Aldrich), b-actin (AC15, Sigma), flag M2 (A-1978, SigmaAldrich), CS (GTX110624, GeneTex), PKM-i1 (SAB4200094, SigmaAldrich), ATP5H (SAB1410095, Sigma-Aldrich), peroxidoxin 6 (HPA006983, Sigma-Aldrich), ALDHL1A1 (AP1465c, Abgent), GPD2 (AP12502B, Abgent), SDHA (GTX101689, GeneTex) and PSA6 (GTX11353, GeneTex), phospho-GSK3b ser9 (5558, Cell Signalling technology), phospho-mTOR (ser2448) (5536, Cell Signalling technology). Infrared-dye conjugated secondary antibodies used were anti-mouse IRDye-800CW and anti-Rabbit IRDye 700CW (Li-Cor Biosciences) and detected using the Odyssey analyser software v2.1 (Li-Cor Biosciences).
qRT-PCR of mRNA levels RNA extractions from fresh-frozen WT and KO cerebella were performed with RNeasy Mini Kit (Qiagen Co) and DNAs were extracted using DNA-free kit (Ambion). RNA was retrotranscribed to cDNA using SuperScript VILO Master Mix (Thermofisher). qRT-PCR was performed with RNA from WT and Atxn1-KO mice cerebella to test levels of gene expression in a multiwell plate format using the LightCycler480 instrument (Roche Diagnostics). Reaction mixtures contained a total volume of 10 ml consisting of 0.1 mM of each primer, 6.25 ng of cDNA and 5 ml of SYBR Premix Ex Taq (Takara). Primer sequences were designed using PrimerEXpress (Thermofisher) and are described in Supplementary Material, 
CS and PKM activity assays
CS activity was determined by measuring the formation of citrate from acetyl CoA (acetyl coenzyme A) and OAA as the absorbance change at 412 nm following addition of DTNB. The reaction was initiated with the addition of 10 ml of the reaction mix (1 mM DTNB, 10% Triton X-100, 8.6 mM acetyl-CoA, 10 mM OAA) to each well containing 10 ml of cerebellar lysate (7-12 mg) from 5-week-old Atxn1-KO mice. Sample readings were performed in triplicate in 384-well plates (3846, Corning, Cultek). Absorbance readings of 412 nm at 1 s intervals were determined using the Varioskan Flash plate reader and analysed with the SkanIT v2.4.1 software (Li-Cor Biosciences). CS activity is expressed as mM TNB/min/mg of cerebellar protein using 13.6 mM À1 cm À1 for extinction coefficient for DTNB and 0.42 cm cell path length. PKM activity was measured by determining the levels of pyruvate by two methods: ATP levels following PKM-mediated PEP conversion to pyruvate and reduction of NAD after lactic acid synthesis from pyruvate as indirect measure of pyruvate levels. To each reaction well, 10 ml of tissue lysate were added to 10 ml of the assay mixture (50 mM Tris-HCl pH 7.5, 10 mM MgCl 2 , 100 mM KCl, 1 mM DTT, 5% Glycerol, 0.6 mM ADP, 0.5 mM PEP, 8 units of LDH, 180 mM NADH with addition or absence of fructose 1,6-bisphosphatase 1 mM (FBP). In the presence of FBP, we determined the total PKM activity (PKM-i1 and PKM-i2) while in its absence only the activity of PKM-i1 was measured. ATP levels remaining after conversion of PEP to pyruvate were determined using the ATPlite luminescence kit (PerkinElmer, Co). The relative PKM activity is expressed as change in ATP levels per mg cerebellar protein. The rate of oxidation of NADH was followed by spectrophotometric measures at 340 nm for 10 min as an indirect indicator of pyruvate levels as it converts to lactate. For each method, sample readings were performed in triplicate in 384-well plates. The extinction coefficient for NADH used was 6.2 mM À1 cm À1 and the cell path length was 0.42 cm. Data are expressed as mM of NADH oxidized/min/mg.
Mitochondria isolation and ETC activity assays
Cerebella from WT or Atxn1-KO mice were dounced homogenized in a sucrose hypotonic buffer 10 mM Hepes, 10 mM KCl, 2 mM EGTA, 5 mM NaF and protease inhibitor cocktail (Roche) at a ratio of 35 mg tissue weight/ml of buffer and incubated on ice for 15 min. The solution was then brought to 320 mM sucrose and for 10 min at 900 g. The supernatant was centrifuged for 10 min at 5000 g. The pellet containing the crude mitochondria fraction was resuspended in 40 mM phosphate buffer, pH 7.4. ETC assays (complexes I, II, III and IV; I and II; and II and III) were carried out using 7-12 lg of freshly isolated mitochondria from the WT and Atxn1-KO mice in 30 ml reaction buffer per well in 384-well plates (3846 Corning, Cultek). The reactions were performed in triplicate for each mitochondria sample per genotype (WT, KO or BO5). All reagents were obtained from Sigma unless otherwise stated. The Varioskan spectrophotometry reader (LI-COR Biosciences) was used to determine the activities at 600 or 550 nm for 10 min. For complex I (NADH: CoQ oxidoreductase, EC 1.6.5.3), 100 lM of 2, 6-Dichlorophenol indophenol (DCIP) was first added to the reaction wells and 200 mM NADH was added 3 min later. DCIP reduction was determined at 600 nm. For complex II (succinate: Co Q oxidoreductase, EC 1.3.5.1), 250 mM of Na-azide and 3 min later 100 mM DCIP was added to the mitochondria samples, followed by addition of 40 mM sodium succinate 1 min later. The reduction of DCIP was followed at 600 nm. The extinction coefficient of DCIP (E mm ¼ 36.0 mM À1 cm À1 (reduced) and the spectrophotometer cell path length of 0.42 cm for the 30 ll reaction per well in the 384-well plate were used to calculate specific activities of complexes I and II. For complex III (CoQ: cytocrome c oxidoreductase, EC 1.10.2.2), 250 lM Na-Azide and 100 lM cytochrome c were added to the reaction followed by addition of 50 lM decylubiquinone after 3 min. The reduction of cytochrome c was measured at 550 nm. For complex IV (cytochrome c oxidase, EC 1.9.3.1), 100 lM cytochrome c and ascorbate were added and the reduction of cytochrome c was measured at 550 nm. The complexes I to III activities were assayed by adding 250 lM Na-Azide and 100 mM cytochrome c followed by addition of 100 mM NADH after 3 min. The reduction of cytochrome c was followed by spectrophotometric readings at 550 nm. The activities of complexes II to III were determined by addition of 250 mM Na-Azide and 100 lM cytochrome c followed by addition of succinate after 3 min. The reduction of cytochrome c was followed at 550 nm. The extinction coefficient of cytochrome c (C3131, Sigma, CAS RN 9007-43-6) used to calculate specific activities of complexes III, IV, complexes 1 to III and complexes II to III was E mm ¼ 28.0 mM À1 cm À1 (cytochrome c reduced). The spectrophotometer cell path length was 0.42 cm for 30 ml reactions per well in 384-well plates. The change in absorbance for all assays was calculated between two points within the linear region.
Determination of basal ATP levels
Basal ATP levels were determined from cerebellar lysates from 5-week-old Atxn1-KO, WT and SCA1 mice using ATPlite-TM 1step kit (PerkinElmer) following the manufacturer's instructions. Each sample was analysed in triplicate using 384-well plates.
Cell culture, transfections, treatments
Human neuroblastoma SH-SY5Y cells grown in Dulbecco's Modified Eagle's medium (DMEM) containing 10% Fetal bovine serum (Sigma), 2 mm glutamine, 50 mg/ml penicillin/streptomycin (Life technologies) at 70% confluence in 10 cm culture dishes using lipofectamine 2000 (Life technologies) and OptiMEM medium (Life technologies) were transfected with 4 mg of flag-tagged ATXN1[30Q] or ATXN1[80Q] plasmid DNAs alone in addition to 0.25 mg EGFP as described (13) . Four hours after transfection, culture medium was replaced with SH-SY5Y culture medium B: neurobasal, B27 supplement, 10 lM retinoic acid, 2 mM glutamine, 50 mg/ml penicillin/streptomycin. Transfected cells were stained with the nuclear fluorescence dye 100 ng/ml 7-amino-actinomycin D (Life Technologies) and the pycnotic nuclei and the soma cell size were visualized and imaged 48 h after transfection using the Axiovert Zeiss Inverted Fluorescence microscope. Quantification was done from images taken from four random fields. For protein analysis, cells were harvested and processed as mentioned earlier. For treatment experiments, cultured cells in 12-well plates (75 000 cells/well) were transfected as earlier and 1 h after medium change were treated with vehicle 0.01% dimethyl sulfoxide (DMSO) or with the GSK3b inhibitor, Tideglusib (2.5 mM) and/or with the mTOR activator, MHY1485 (2.5 mM), both purchased from Sigma. Treated cells were harvested and processed as earlier.
Statistics
Statistical data were analysed with SPSS 21.0 (IBM Corp.) or StatPlus software (AnalystSoft Inc.). Data were tested for normal distribution and equality of variances using the Shapiro-Wilks' W-test and the Levene's test of homogeneity of variances, respectively. Normally distributed data were analysed by one-way ANOVA followed by post hoc comparisons with either the Tukey HSD (honestly significant difference test) for groups of data with equal variances or, alternatively, with the Games-Howell test in one-way ANOVA analyses with unequal variances. Those values that did not meet one of the two assumptions were individually tested with non-parametric test Mann-Whitney U test, to demonstrate significant variations between both groups in all of them. Statistical significance was defined as a P < 0.05. 2D-DIGE protein spots identified were also analysed with the non-parametric SAM test (86) . SAM v3.09 was obtained from Stanford University as a R-package v2.11.1. Statistical significance was defined as a P-value < 0.05. SEM denotes for standard error of the mean.
Supplementary Material
Supplementary Material is available at HMG online.
